{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=55", "query": { "condition": "Ovarian Tumors", "page": 55 }, "page_size": 10 }, "pagination": { "page": 55, "page_size": 10, "total_count": 2464, "total_pages": 247, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=56&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ovarian+Tumors&page=54&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T08:40:05.054Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00972205", "title": "Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical", "Ovarian", "Lung", "Breast", "Renal" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "CBT-1(Registered Trademark)", "type": "DRUG" }, { "name": "Tc 99m sestamibi", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 12, "start_date": "2007-12", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2012-07-19", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00972205" }, { "nct_id": "NCT06751329", "title": "A Study of DM002 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Neoplasms", "Prostatic Neoplasms", "Endometrial Neoplasms", "Colorectal Neoplasms", "Solid Carcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "DM002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Xadcera Biopharmaceutical (Suzhou) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 280, "start_date": "2025-02-17", "completion_date": "2028-04-18", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 4, "location_summary": "San Francisco, California • Huntersville, North Carolina • Oklahoma City, Oklahoma + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06751329" }, { "nct_id": "NCT00551070", "title": "Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Ovarian Serous Tumor", "Low Grade Ovarian Serous Adenocarcinoma", "Micropapillary Serous Carcinoma", "Primary Peritoneal Carcinoma", "Primary Peritoneal Low Grade Serous Adenocarcinoma", "Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 52, "start_date": "2007-12-17", "completion_date": "2020-11-13", "has_results": true, "last_update_posted_date": "2020-12-03", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 49, "location_summary": "Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 32 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551070" }, { "nct_id": "NCT00002717", "title": "Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 324, "start_date": "1996-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 52, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002717" }, { "nct_id": "NCT03162562", "title": "The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer of Ovary", "Neoplasms, Ovarian", "Ovarian Cancer Stage IV", "Ovarian Cancer Recurrent", "Ovarian Cancer Stage III", "Ovary Cancer" ], "interventions": [ { "name": "Oregovomab", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "CanariaBio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "FEMALE", "summary": "18 Years to 90 Years · Female only" }, "enrollment_count": 10, "start_date": "2017-05-30", "completion_date": "2020-11-05", "has_results": false, "last_update_posted_date": "2020-12-22", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 2, "location_summary": "Orlando, Florida • Richmond, Virginia", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03162562" }, { "nct_id": "NCT04905082", "title": "HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Carcinoma", "Colorectal Carcinoma", "Lung Carcinoma", "Malignant Solid Neoplasm", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Prostate Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Genomic Profile", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 465, "start_date": "2021-12-30", "completion_date": "2026-10-01", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04905082" }, { "nct_id": "NCT04931823", "title": "Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "CPO-100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Conjupro Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-03-24", "completion_date": "2024-08-26", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 8, "location_summary": "Los Angeles, California • New Haven, Connecticut • Las Vegas, Nevada + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Lyndhurst", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04931823" }, { "nct_id": "NCT00277290", "title": "Study of XL999 in Patients With Previously Treated Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "XL999", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphony Evolution, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 24, "start_date": "2006-01", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2010-02-22", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 9, "location_summary": "Greenbrae, California • Port Saint Lucie, Florida • Chicago, Illinois + 6 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Joliet", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00277290" }, { "nct_id": "NCT04152018", "title": "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Ovarian Cancer", "Gastric Cancer", "Esophageal Cancer", "Lung Squamous Cell Carcinoma", "Pancreatic Cancer", "Bile Duct Cancer", "Endometrial Cancer", "Melanoma Cancer", "Urothelial Cancer" ], "interventions": [ { "name": "PF-06940434", "type": "DRUG" }, { "name": "PF-06801591", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-11-13", "completion_date": "2024-12-10", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 18, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04152018" }, { "nct_id": "NCT06065059", "title": "Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Ovarian Cancer", "Pancreas Cancer", "Prostate Cancer", "BRCA1 Mutation", "BRCA-Mutated Ovarian Carcinoma", "BRCA-Associated Breast Carcinoma", "HRD Positive Advanced Ovarian Cancer" ], "interventions": [ { "name": "TNG348", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tango Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-12-08", "completion_date": "2024-05-22", "has_results": false, "last_update_posted_date": "2024-08-13", "last_synced_at": "2026-10-24T08:40:05.054Z", "location_count": 7, "location_summary": "Denver, Colorado • Orange City, Florida • Sarasota, Florida + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Orange City", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06065059" } ] }